The role of drug transporters in the kidney: Lessons from tenofovir

Frontiers in Pharmacology

Volumn 5, Issue NOV, 2014, Pages

  Moss, Darren M ^a   Neary, Megan ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Drug transporters; Kidney; Pharmacokinetics; Tenofovir; Toxicity

Indexed keywords

ABC TRANSPORTER; ACICLOVIR; ATAZANAVIR PLUS RITONAVIR; CARRIER PROTEIN; CEFMETAZOLE; CIDOFOVIR; CIMETIDINE; CREATININE; DARUNAVIR PLUS RITONAVIR; DICLOFENAC; DIDANOSINE; DIGOXIN; FEXOFENADINE; LOPINAVIR PLUS RITONAVIR; METFORMIN; N(G),N(G) DIMETHYLARGININE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; OSELTAMIVIR; PROBENECID; QUINIDINE; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; TENOFOVIR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG POTENTIATION; DRUG TOXICITY; FANCONI RENOTUBULAR SYNDROME; GENETIC ASSOCIATION; GLOMERULUS FILTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; KIDNEY FAILURE; KIDNEY TUBULE EXCRETION; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; PHARMACOGENETICS; PROTEINURIA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUBULAR DYSFUNCTION; UNSPECIFIED SIDE EFFECT;

EID: 84910629450     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00248     Document Type: Review

References (164)

1. Bakos, E., and Homolya, L. (2007). Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch. 453, 621-641. doi: 10.1007/s00424-006-0160-8
2. Ballabh, P., Braun, A., and Nedergaard, M. (2004). The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1-13. doi: 10.1016/j.nbd.2003.12.016
3. Bam, R. A., Yant, S. R., and Cihlar, T. (2014). Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir. Ther. doi: 10.3851/IMP2770 [Epub ahead of print].
4. Barditch-Crovo, P., Deeks, S. G., Collier, A., Safrin, S., Coakley, D. F., Miller, M.,et al. (2001). Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45, 2733-2739. doi: 10.1128/AAC.45.10.2733-2739.2001
5. Barone, S., Amlal, H., Xu, J., and Soleimani, M. (2012). Deletion of the Cl-/HCO3- exchanger pendrin downregulates calcium-absorbing proteins in the kidney and causes calcium wasting. Nephrol. Dial. Transplant. 27, 1368-1379. doi: 10.1093/ndt/gfr505
6. Beery, E., Rajnai, Z., Abonyi, T., Makai, I., Bansaghi, S., Erdo, F.,et al. (2011). ABCG2 modulates chlorothiazide permeability in vitro - characterization of the interaction. Drug Metab. Pharmacokinet. 27, 349-353. doi: 10.2133/dmpk.DMPK-11-NT-068
7. Bender, B. S. (2013). Prophylactic tenofovir reduced HIV infection in injectable drug users. Ann. Intern. Med. 159, JC8. doi: 10.7326/0003-4819-159-6-201309170-02008
8. Berglund, F., Killander, J., and Pompeius, R. (1975). Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J. Urol. 114, 802-808.
9. Bernard, A. M., Vyskocil, A., Mahieu, P., and Lauwerys, R. (1987). Assessment of urinary retinol-binding protein as an index of proximal tubular injury. Clin. Chem. 33, 775-779.
10. Bhutia, Y. D., Hung, S. W., Patel, B., Lovin, D., and Govindarajan, R. (2011). CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res. 71, 1825-1835. doi: 10.1158/0008-5472.CAN-10-2736
11. Bickel, M., Khaykin, P., Stephan, C., Schmidt, K., Buettner, M., Amann, K.,et al. (2013). Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. HIV Med. 14, 633-638. doi: 10.1111/hiv.12072
12. Bleasby, K., Castle, J. C., Roberts, C. J., Cheng, C., Bailey, W. J., Sina, J. F.,et al. (2006). Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36, 963-988. doi: 10.1080/00498250600861751
13. Boffito, M., Pozniak, A., Kearney, B. P., Higgs, C., Mathias, A., Zhong, L.,et al. (2005). Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. Antimicrob. Agents Chemother. 49, 4386-4389. doi: 10.1128/AAC.49.10.4386-4389.2005
14. Braun, D., Wirth, E. K., Wohlgemuth, F., Reix, N., Klein, M. O., Gruters, A.,et al. (2011). Aminoaciduria, but normal thyroid hormone levels and signalling, in mice lacking the amino acid and thyroid hormone transporter Slc7a8. Biochem. J. 439, 249-255. doi: 10.1042/BJ20110759
15. Calza, L., Trapani, F., Salvadori, C., Magistrelli, E., Manfredi, R., Colangeli, V.,et al. (2013). Incidence of renal toxicity in HIV-infected, antiretroviral-naive patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir. Scand. J. Infect. Dis. 45, 147-154. doi: 10.3109/00365548.2012.712213
16. Calza, L., Trapani, F., Tedeschi, S., Piergentili, B., Manfredi, R., Colangeli, V.,et al. (2011). Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients. Scand. J. Infect. Dis. 43, 656-660. doi: 10.3109/00365548.2011.572906
17. Cha, S. H., Sekine, T., Kusuhara, H., Yu, E., Kim, J. Y., Kim, D. K.,et al. (2000). Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J. Biol. Chem. 275, 4507-4512. doi: 10.1074/jbc.275.6.4507
18. Chen, Y., Zhang, S., Sorani, M., and Giacomini, K. M. (2007). Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J. Pharmacol. Exp. Ther. 322, 695-700. doi: 10.1124/jpet.107.123554
19. Chen, Z. S., Hopper-Borge, E., Belinsky, M. G., Shchaveleva, I., Kotova, E., and Kruh, G. D. (2003). Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol. 63, 351-358. doi: 10.1124/mol.63.2.351
20. Choi, M. K., Kim, M. H., Maeng, H. J., and Song, I. S. (2014). Contribution of CNT1 and ENT1 to ribavirin uptake in human hepatocytes. Arch. Pharm. Res. doi: 10.1007/s12272-014-0437-y [Epub ahead of print].
21. Choudhury, D., and Ahmed, Z. (2006). Drug-associated renal dysfunction and injury. Nat. Clin. Pract. Nephrol. 2, 80-91. doi: 10.1038/ncpneph0076
22. Christiansen-Weber, T. A., Voland, J. R., Wu, Y., Ngo, K., Roland, B. L., Nguyen, S.,et al. (2000). Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency. Am. J. Pathol. 157, 1017-1029. doi: 10.1016/S0002-9440(10)64614-7
23. Ciarimboli, G., Lancaster, C. S., Schlatter, E., Franke, R. M., Sprowl, J. A., Pavenstadt, H.,et al. (2012). Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin. Cancer Res. 18, 1101-1108. doi: 10.1158/1078-0432.CCR-11-2503
24. Cihlar, T., Ray, A. S., Laflamme, G., Vela, J. E., Tong, L., Fuller, M. D.,et al. (2007). Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir. Ther. 12, 267-272.
25. Cooper, R. D., Wiebe, N., Smith, N., Keiser, P., Naicker, S., and Tonelli, M. (2010). Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin. Infect. Dis. 51, 496-505. doi: 10.1086/655681
26. Cote, H. C., Magil, A. B., Harris, M., Scarth, B. J., Gadawski, I., Wang, N.,et al. (2006). Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir. Ther. 11, 79-86.
27. Cundy, K. C., Petty, B. G., Flaherty, J., Fisher, P. E., Polis, M. A., Wachsman, M.,et al. (1995). Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39, 1247-1252. doi: 10.1128/AAC.39.6.1247
28. Daniel, H., and Kottra, G. (2004). The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 447, 610-618. doi: 10.1007/s00424-003-1101-4
29. Dawson, P. A., Beck, L., and Markovich, D. (2003). Hyposulfatemia, growth retardation, reduced fertility, and seizures in mice lacking a functional NaSi-1 gene. Proc. Natl. Acad. Sci. U.S.A. 100, 13704-13709. doi: 10.1073/pnas.2231298100
30. Dawson, P. A., Russell, C. S., Lee, S., Mcleay, S. C., Van Dongen, J. M., Cowley, D. M.,et al. (2010). Urolithiasis and hepatotoxicity are linked to the anion transporter Sat1 in mice. J. Clin. Invest. 120, 706-712. doi: 10.1172/JCI31474
31. de Geus, H. R., Betjes, M. G., and Bakker, J. (2012). Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin. Kidney J. 5, 102-108. doi: 10.1093/ckj/sfs008
32. De Lannoy, I. A., Koren, G., Klein, J., Charuk, J., and Silverman, M. (1992). Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am. J. Physiol. 263, F613-F622.
33. Deeley, R. G., Westlake, C., and Cole, S. P. (2006). Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86, 849-899. doi: 10.1152/physrev.00035.2005
34. DeGorter, M. K., Xia, C. Q., Yang, J. J., and Kim, R. B. (2012). Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol. 52, 249-273. doi: 10.1146/annurev-pharmtox-010611-134529
35. Del Palacio, M., Romero, S., and Casado, J. L. (2012). Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev. 14, 179-187.
36. Devarajan, P. (2008). Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand. J. Clin. Lab. Invest. 68, 89-94. doi: 10.1080/00365510802150158
37. Dickson, L. E., Wagner, M. C., Sandoval, R. M., and Molitoris, B. A. (2014). The proximal tubule and albuminuria: really! J. Am. Soc. Nephrol. 25, 443-453. doi: 10.1681/ASN.2013090950
38. Ding, R., Tayrouz, Y., Riedel, K. D., Burhenne, J., Weiss, J., Mikus, G.,et al. (2004). Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 76, 73-84. doi: 10.1016/j.clpt.2004.02.008
39. Dresser, M. J., Leabman, M. K., and Giacomini, K. M. (2001). Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci. 90, 397-421. doi: 10.1002/1520-6017(200104)90:4<397::AID-JPS1000>3.0.CO;2-D
40. El-Sheikh, A. A., Van Den Heuvel, J. J., Koenderink, J. B., and Russel, F. G. (2007). Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 320, 229-235. doi: 10.1124/jpet.106.110379
41. Endres, C. J., Moss, A. M., Ke, B., Govindarajan, R., Choi, D. S., Messing, R. O.,et al. (2009). The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. J. Pharmacol. Exp. Ther. 329, 387-398. doi: 10.1124/jpet.108.145854
42. Enomoto, A., Kimura, H., Chairoungdua, A., Shigeta, Y., Jutabha, P., Cha, S. H.,et al. (2002). Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417, 447-452. doi: 10.1038/nature742
43. Eraly, S. A., Vallon, V., Rieg, T., Gangoiti, J. A., Wikoff, W. R., Siuzdak, G.,et al. (2008). Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol. Genomics 33, 180-192. doi: 10.1152/physiolgenomics.00207.2007
44. Eraly, S. A., Vallon, V., Vaughn, D. A., Gangoiti, J. A., Richter, K., Nagle, M.,et al. (2006). Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J. Biol. Chem. 281, 5072-5083. doi: 10.1074/jbc.M508050200
45. Estrella, M. M., and Fine, D. M. (2010). Screening for chronic kidney disease in HIV-infected patients. Adv. Chronic Kidney Dis. 17, 26-35. doi: 10.1053/j.ackd.2009.07.014
46. Estudante, M., Morais, J. G., Soveral, G., and Benet, L. Z. (2013). Intestinal drug transporters: an overview. Adv. Drug Deliv. Rev. 65, 1340-1356. doi: 10.1016/j.addr.2012.09.042
47. Faber, K. N., Muller, M., and Jansen, P. L. (2003). Drug transport proteins in the liver. Adv. Drug Deliv. Rev. 55, 107-124. doi: 10.1016/S0169-409X(02)00173-4
48. Fassett, R. G., Venuthurupalli, S. K., Gobe, G. C., Coombes, J. S., Cooper, M. A., and Hoy, W. E. (2011). Biomarkers in chronic kidney disease: a review. Kidney Int. 80, 806-821. doi: 10.1038/ki.2011.198
49. Feliubadalo, L., Arbones, M. L., Manas, S., Chillaron, J., Visa, J., Rodes, M.,et al. (2003). Slc7a9-deficient mice develop cystinuria non-I and cystine urolithiasis. Hum. Mol. Genet. 12, 2097-2108. doi: 10.1093/Hmg/Ddg228
50. Fenster, P. E., Powell, J. R., Graves, P. E., Conrad, K. A., Hager, W. D., Goldman, S.,et al. (1980). Digitoxin-quinidine interaction: pharmacokinetic evaluation. Ann. Intern. Med. 93, 698-701. doi: 10.7326/0003-4819-93-5-698
51. Fenton, R. A., Chou, C. L., Stewart, G. S., Smith, C. P., and Knepper, M. A. (2004). Urinary concentrating defect in mice with selective deletion of phloretin-sensitive urea transporters in the renal collecting duct. Proc. Natl. Acad. Sci. U.S.A. 101, 7469-7474. doi: 10.1073/pnas.0401704101
52. Fernandez-Fernandez, B., Montoya-Ferrer, A., Sanz, A. B., Sanchez-Nino, M. D., Izquierdo, M. C., Poveda, J.,et al. (2011). Tenofovir nephrotoxicity: 2011 update. AIDS Res. Treat. 2011:354908. doi: 10.1155/2011/354908
53. Ford, J., Khoo, S. H., and Back, D. J. (2004). The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 54, 982-990. doi: 10.1093/jac/dkh487
54. Ganapathy, M. E., Brandsch, M., Prasad, P. D., Ganapathy, V., and Leibach, F. H. (1995). Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J. Biol. Chem. 270, 25672-25677. doi: 10.1074/jbc.270.43.25672
55. Ganapathy, M. E., Huang, W., Wang, H., Ganapathy, V., and Leibach, F. H. (1998). Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 246, 470-475. doi: 10.1006/bbrc.1998.8628
56. German, P., Liu, H. C., Szwarcberg, J., Hepner, M., Andrews, J., Kearney, B. P.,et al. (2012). Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J. Acquir. Immune Defic. Syndr. 61, 32-40. doi: 10.1097/QAI.0b013e3182645648
57. Goicoechea, M., Liu, S., Best, B., Sun, S., Jain, S., Kemper, C.,et al. (2008). Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J. Infect. Dis. 197, 102-108. doi: 10.1086/524061
58. Gorboulev, V., Ulzheimer, J. C., Akhoundova, A., Ulzheimer-Teuber, I., Karbach, U., Quester, S.,et al. (1997). Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16, 871-881. doi: 10.1089/dna.1997.16.871
59. Goren, M. P., Wright, R. K., and Horowitz, M. E. (1986). Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother. Pharmacol. 18, 69-73. doi: 10.1007/BF00253068
60. Grundemann, D., Liebich, G., Kiefer, N., Koster, S., and Schomig, E. (1999). Selective substrates for non-neuronal monoamine transporters. Mol. Pharmacol. 56, 1-10.
61. Gupta, S. K., Anderson, A. M., Ebrahimi, R., Fralich, T., Graham, H., Scharen-Guivel, V.,et al. (2014). Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS ONE 9:e92717. doi: 10.1371/journal.pone.0092717
62. Hagos, Y., Stein, D., Ugele, B., Burckhardt, G., and Bahn, A. (2007). Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J. Am. Soc. Nephrol. 18, 430-439. doi: 10.1681/ASN.2006040415
63. Hagos, Y., and Wolff, N. A. (2010). Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins (Basel) 2, 2055-2082. doi: 10.3390/toxins2082055
64. Hall, A. M., Hendry, B. M., Nitsch, D., and Connolly, J. O. (2011). Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am. J. Kidney Dis. 57, 773-780. doi: 10.1053/j.ajkd.2011.01.022
65. Han, W. K., Bailly, V., Abichandani, R., Thadhani, R., and Bonventre, J. V. (2002). Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 62, 237-244. doi: 10.1046/j.1523-1755.2002.00433.x
66. Herget-Rosenthal, S., Marggraf, G., Hüsing, J., Göring, F., Pietruck, F., Janssen, O.,et al. (2004). Early detection of acute renal failure by serum cystatin C. Kidney Int. 66, 1115-1122. doi: 10.1111/j.1523-1755.2004.00861.x
67. Hill, G., Cihlar, T., Oo, C., Ho, E. S., Prior, K., Wiltshire, H.,et al. (2002). The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab. Dispos. 30, 13-19. doi: 10.1124/dmd.30.1.13
68. Ho, E. S., Lin, D. C., Mendel, D. B., and Cihlar, T. (2000). Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 11, 383-393.
69. Hopper-Borge, E., Xu, X., Shen, T., Shi, Z., Chen, Z. S., and Kruh, G. D. (2009). Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 69, 178-184. doi: 10.1158/0008-5472.CAN-08-1420
70. Imaoka, T., Kusuhara, H., Adachi, M., Schuetz, J. D., Takeuchi, K., and Sugiyama, Y. (2007). Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol. 71, 619-627. doi: 10.1124/mol.106.028233
71. Izzedine, H., Hulot, J. S., Villard, E., Goyenvalle, C., Dominguez, S., Ghosn, J.,et al. (2006). Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J. Infect. Dis. 194, 1481-1491. doi: 10.1086/508546
72. Izzedine, H., Kheder-Elfekih, R., Housset, P., Sarkozy, C., Brocheriou, I., and Deray, G. (2009). Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. AIDS 23, 544-545. doi: 10.1097/QAD.0b013e32832407f7
73. Jani, M., Szabo, P., Kis, E., Molnar, E., Glavinas, H., and Krajcsi, P. (2009). Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. Biol. Pharm. Bull. 32, 497-499. doi: 10.1248/bpb.32.497
74. Johnson, D. J., Owen, A., Plant, N., Bray, P. G., and Ward, S. A. (2008). Drug-regulated expression of Plasmodium falciparum P-glycoprotein homologue 1: a putative role for nuclear receptors. Antimicrob. Agents Chemother. 52, 1438-1445. doi: 10.1128/AAC.01392-07
75. Jonker, J. W., Wagenaar, E., Van Eijl, S., and Schinkel, A. H. (2003). Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol. Cell. Biol. 23, 7902-7908. doi: 10.1128/MCB.23.21.7902-7908.2003
76. Juhasz, V., Beery, E., Nagy, Z., Bui, A., Molnar, E., Zolnerciks, J. K.,et al. (2013). Chlorothiazide is a substrate for the human uptake transporters OAT1 and OAT3. J. Pharm. Sci. 102, 1683-1687. doi: 10.1002/jps.23491
77. Kage, K., Tsukahara, S., Sugiyama, T., Asada, S., Ishikawa, E., Tsuruo, T.,et al. (2002). Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer 97, 626-630. doi: 10.1002/ijc.10100
78. Kamal, M. A., Keep, R. F., and Smith, D. E. (2008). Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity. Drug Metab. Pharmacokinet. 23, 236-242. doi: 10.2133/dmpk.23.236
79. Kelly, M. D., Gibson, A., Bartlett, H., Rowling, D., and Patten, J. (2013). Tenofovir-associated proteinuria. AIDS 27, 479-481. doi: 10.1097/QAD.0b013e32835883bf
80. Kimura, H., Takeda, M., Narikawa, S., Enomoto, A., Ichida, K., and Endou, H. (2002). Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J. Pharmacol. Exp. Ther. 301, 293-298. doi: 10.1124/jpet.301.1.293
81. Kis, O., Robillard, K., Chan, G. N., and Bendayan, R. (2010). The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol. Sci. 31, 22-35. doi: 10.1016/j.tips.2009.10.001
82. Kiser, J. J., Aquilante, C. L., Anderson, P. L., King, T. M., Carten, M. L., and Fletcher, C. V. (2008a). Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 47, 298-303. doi: 10.1097/QAI.0b013e31815e7478
83. Kiser, J. J., Carten, M. L., Aquilante, C. L., Anderson, P. L., Wolfe, P., King, T. M.,et al. (2008b). The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin. Pharmacol. Ther. 83, 265-272. doi: 10.1038/sj.clpt.6100269
84. Ko, H., Cathcart, K. S., Griffith, D. L., Peters, G. R., and Adams, W. J. (1989). Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. Antimicrob. Agents Chemother. 33, 356-361. doi: 10.1128/AAC.33.3.356
85. Kobayashi, Y., Ohshiro, N., Sakai, R., Ohbayashi, M., Kohyama, N., and Yamamoto, T. (2005). Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J. Pharm. Pharmacol. 57, 573-578. doi: 10.1211/0022357055966
86. Kohler, J. J., Hosseini, S. H., Green, E., Abuin, A., Ludaway, T., Russ, R.,et al. (2011). Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab. Invest. 91, 852-858. doi: 10.1038/labinvest.2011.48
87. Kool, M., Van Der Linden, M., De Haas, M., Baas, F., and Borst, P. (1999a). Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 59, 175-182.
88. Kool, M., van Der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M., Smith, A. J.,et al. (1999b). MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. U.S.A. 96, 6914-6919. doi: 10.1073/pnas.96.12.6914
89. Koteff, J., Borland, J., Chen, S., Song, I., Peppercorn, A., Koshiba, T.,et al. (2013). A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br. J. Clin. Pharmacol. 75, 990-996. doi: 10.1111/j.1365-2125.2012.04440.x
90. Kusuhara, H., Sekine, T., Utsunomiya-Tate, N., Tsuda, M., Kojima, R., Cha, S. H.,et al. (1999). Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J. Biol. Chem. 274, 13675-13680. doi: 10.1074/jbc.274.19.13675
91. Lalande, L., Charpiat, B., Leboucher, G., and Tod, M. (2014). Consequences of renal failure on non-renal clearance of drugs. Clin. Pharmacokinet. 53, 521-532. doi: 10.1007/s40262-014-0146-1
92. Laskin, O. L., De Miranda, P., King, D. H., Page, D. A., Longstreth, J. A., Rocco, L.,et al. (1982). Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob. Agents Chemother. 21, 804-807. doi: 10.1128/AAC.21.5.804
93. Lee, H. W., Verlander, J. W., Bishop, J. M., Igarashi, P., Handlogten, M. E., and Weiner, I. D. (2009). Collecting duct-specific Rh C glycoprotein deletion alters basal and acidosis-stimulated renal ammonia excretion. Am. J. Physiol. Renal Physiol. 296, F1364-F1375. doi: 10.1152/ajprenal.90667.2008
94. Lepist, E.-I., Zhang, X., Hao, J., Huang, J., Kosaka, A., Birkus, G.,et al. (2014). Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int. 86, 350-357. doi: 10.1038/ki.2014.66
95. Leviel, F., Hubner, C. A., Houillier, P., Morla, L., El Moghrabi, S., Brideau, G.,et al. (2010). The Na+-dependent chloride-bicarbonate exchanger SLC4A8 mediates an electroneutral Na+ reabsorption process in the renal cortical collecting ducts of mice. J. Clin. Invest. 120, 1627-1635. doi: 10.1172/JCI40145
96. Liang, R., Fei, Y. J., Prasad, P. D., Ramamoorthy, S., Han, H., Yang-Feng, T. L.,et al. (1995). Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J. Biol. Chem. 270, 6456-6463.
97. Liptrott, N. J., Pushpakom, S., Wyen, C., Fatkenheuer, G., Hoffmann, C., Mauss, S.,et al. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet. Genomics 22, 10-19. doi: 10.1097/FPC.0b013e32834dd82e
98. Markowitz, M., Zolopa, A., Squires, K., Ruane, P., Coakley, D., Kearney, B.,et al. (2014). Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J. Antimicrob. Chemother. 69, 1362-1369. doi: 10.1093/jac/dkt532
99. Martin, P., Riley, R., Back, D. J., and Owen, A. (2008). Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br. J. Pharmacol. 153, 805-819. doi: 10.1038/sj.bjp.0707601
100. Martinez-Guerrero, L. J., and Wright, S. H. (2013). Substrate-dependent inhibition of human MATE1 by cationic ionic liquids. J. Pharmacol. Exp. Ther. 346, 495-503. doi: 10.1124/jpet.113.204206
101. Masuda, S., Terada, T., Yonezawa, A., Tanihara, Y., Kishimoto, K., Katsura, T.,et al. (2006). Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 17, 2127-2135. doi: 10.1681/ASN.2006030205
102. Morris, M. E., Lee, H. J., and Predko, L. M. (2003). Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol. Rev. 55, 229-240. doi: 10.1124/pr.55.2.1
103. Morrissey, K. M., Stocker, S. L., Wittwer, M. B., Xu, L., and Giacomini, K. M. (2013). Renal transporters in drug development. Annu. Rev. Pharmacol. Toxicol. 53, 503-529. doi: 10.1146/annurev-pharmtox-011112-140317
104. Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H.,et al. (2011). Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 55, 879-887. doi: 10.1128/AAC.00623-10
105. Motohashi, H., and Inui, K.-I. (2013). Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J. 15, 581-588. doi: 10.1208/s12248-013-9465-7
106. Nagai, K., Nagasawa, K., Koma, M., Hotta, A., and Fujimoto, S. (2006). Cytidine is a novel substrate for wild-type concentrative nucleoside transporter 2. Biochem. Biophys. Res. Commun. 347, 439-443. doi: 10.1016/j.bbrc.2006.06.103
107. Neumanova, Z., Cerveny, L., Ceckova, M., and Staud, F. (2014). Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. AIDS 28, 9-17. doi: 10.1097/QAD.0000000000000112
108. Nies, A. T., Koepsell, H., Damme, K., and Schwab, M. (2011). Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb. Exp. Pharmacol. 201, 105-167. doi: 10.1007/978-3-642-14541-4_3
109. Nishijima, T., Komatsu, H., Higasa, K., Takano, M., Tsuchiya, K., Hayashida, T.,et al. (2012). Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study. Clin. Infect. Dis. 55, 1558-1567. doi: 10.1093/cid/cis772
110. Ocheltree, S. M., Shen, H., Hu, Y., Keep, R. F., and Smith, D. E. (2005). Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J. Pharmacol. Exp. Ther. 315, 240-247. doi: 10.1124/jpet.105.089359
111. Ohana, E., Shcheynikov, N., Moe, O. W., and Muallem, S. (2013). SLC26A6 and NaDC-1 transporters interact to regulate oxalate and citrate homeostasis. J. Am. Soc. Nephrol. 24, 1617-1626. doi: 10.1681/ASN.2013010080
112. Ohi, A., Hanabusa, E., Ueda, O., Segawa, H., Horiba, N., Kaneko, I.,et al. (2011). Inorganic phosphate homeostasis in sodium-dependent phosphate cotransporter Npt2b(+)/(-) mice. Am. J. Physiol. Renal Physiol. 301, F1105-F1113. doi: 10.1152/ajprenal.00663.2010
113. Ohta, K. Y., Inoue, K., Hayashi, Y., and Yuasa, H. (2006). Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab. Dispos. 34, 1868-1874. doi: 10.1124/dmd.106.010876
114. Ortiz, A., Justo, P., Sanz, A., Melero, R., Caramelo, C., Guerrero, M. F.,et al. (2005). Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir. Ther. 10, 185-190.
115. Owen, A., Chandler, B., Back, D. J., and Khoo, S. H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir. Ther. 9, 819-821.
116. Preitner, F., Bonny, O., Laverriere, A., Rotman, S., Firsov, D., Da Costa, A.,et al. (2009). Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc. Natl. Acad. Sci. U.S.A. 106, 15501-15506. doi: 10.1073/pnas.0904411106
117. Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M.,et al. (2011). Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J. Infect. Dis. 204, 145-153. doi: 10.1093/infdis/jir215
118. Quan, H., Athirakul, K., Wetsel, W. C., Torres, G. E., Stevens, R., Chen, Y. T.,et al. (2004). Hypertension and impaired glycine handling in mice lacking the orphan transporter XT2. Mol. Cell. Biol. 24, 4166-4173. doi: 10.1128/MCB.24.10.4166-4173.2004
119. Ray, A. S., Cihlar, T., Robinson, K. L., Tong, L., Vela, J. E., Fuller, M. D.,et al. (2006). Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. 50, 3297-3304. doi: 10.1128/AAC.00251-06
120. Ray, A. S., Olson, L., and Fridland, A. (2004). Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. 48, 1089-1095. doi: 10.1128/AAC.48.4.1089-1095.2004
121. Reginato, A. M., Mount, D. B., Yang, I., and Choi, H. K. (2012). The genetics of hyperuricaemia and gout. Nat. Rev. Rheumatol. 8, 610-621. doi: 10.1038/nrrheum.2012.144
122. Robbins, N., Koch, S. E., Tranter, M., and Rubinstein, J. (2012). The history and future of probenecid. Cardiovasc. Toxicol. 12, 1-9. doi: 10.1007/s12012-011-9145-8
123. Robertshaw, M., Lai, K., and Swaminathan, R. (1989). Prediction of creatinine clearance from plasma creatinine: comparison of five formulae. Br. J. Clin. Pharmacol. 28, 275-280. doi: 10.1111/j.1365-2125.1989.tb05427.x
124. Rodriguez-Novoa, S., Alvarez, E., Labarga, P., and Soriano, V. (2010). Renal toxicity associated with tenofovir use. Expert Opin. Drug Saf. 9, 545-559. doi: 10.1517/14740331003627458
125. Rodriguez-Novoa, S., Labarga, P., and Soriano, V. (2009a). Pharmacogenetics of tenofovir treatment. Pharmacogenomics 10, 1675-1685. doi: 10.2217/pgs.09.115
126. Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J.,et al. (2009b). Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin. Infect. Dis. 48, e108-e116. doi: 10.1086/598507
127. Sato, K., Sai, Y., Nishimura, T., Chishu, T., Shimpo, S., Kose, N.,et al. (2009). Influx mechanism of 2′,3′-dideoxyinosine and uridine at the blood-placenta barrier. Placenta 30, 263-269. doi: 10.1016/j.placenta.2008.11.022
128. Sax, P. E., Zolopa, A., Brar, I., Elion, R., Ortiz, R., Post, F.,et al. (2014). Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J. Acquir. Immune Defic. Syndr. 67, 52-58. doi: 10.1097/QAI.0000000000000225
129. Scheffer, G. L., Kool, M., De Haas, M., De Vree, J. M., Pijnenborg, A. C., Bosman, D. K.,et al. (2002). Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. 82, 193-201. doi: 10.1038/labinvest.3780411
130. Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S.,et al. (2010). Population pharmacokinetic modeling of the association between 63396C- > T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob. Agents Chemother. 54, 5242-5250. doi: 10.1128/AAC.00781-10
131. Schultheis, P. J., Clarke, L. L., Meneton, P., Miller, M. L., Soleimani, M., Gawenis, L. R.,et al. (1998). Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger. Nat. Genet. 19, 282-285. doi: 10.1038/969
132. Schwedhelm, E., and Böger, R. H. (2011). The role of asymmetric and symmetric dimethylarginines in renal disease. Nat. Rev. Nephrol. 7, 275-285. doi: 10.1038/nrneph.2011.31
133. Shafiu, M., Johnson, R. J., Turner, S. T., Langaee, T., Gong, Y., Chapman, A. B.,et al. (2012). Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press. Res. 35, 477-482. doi: 10.1159/000337370
134. Shen, H., Smith, D. E., and Brosius, F. C. III. (2001). Developmental expression of PEPT1 and PEPT2 in rat small intestine, colon, and kidney. Pediatr. Res. 49, 789-795. doi: 10.1203/00006450-200106000-00013
135. Shu, C., Shen, H., Hopfer, U., and Smith, D. E. (2001). Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. Drug Metab. Dispos. 29, 1307-1315.
136. Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D.,et al. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C- > T) with reduced concentrations of unboosted atazanavir. Clin. Infect. Dis. 47, 1222-1225. doi: 10.1086/592304
137. Smeets, P. H., Van Aubel, R. A., Wouterse, A. C., Van Den Heuvel, J. J., and Russel, F. G. (2004). Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J. Am. Soc. Nephrol. 15, 2828-2835. doi: 10.1097/01.ASN.0000143473.64430.AC
138. Solomon, M. M., Lama, J. R., Glidden, D. V., Mulligan, K., Mcmahan, V., Liu, A. Y.,et al. (2014). Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS 28, 851-859. doi: 10.1097/QAD.0000000000000156
139. Somogyi, A., Stockley, C., Keal, J., Rolan, P., and Bochner, F. (1987). Reduction of metformin renal tubular secretion by cimetidine in man. Br. J. Clin. Pharmacol. 23, 545-551. doi: 10.1111/j.1365-2125.1987.tb03090.x
140. Sun, Y. L., Chen, J. J., Kumar, P., Chen, K., Sodani, K., Patel, A.,et al. (2013). Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS ONE 8:e55576. doi: 10.1371/journal.pone.0055576
141. Sun, Y. L., Kumar, P., Sodani, K., Patel, A., Pan, Y., Baer, M. R.,et al. (2014). Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncol. Rep. 31, 1605-1612. doi: 10.3892/or.2014.3002
142. Tanigawara, Y. (2000). Role of P-glycoprotein in drug disposition. Ther. Drug Monit. 22, 137-140. doi: 10.1097/00007691-200002000-00029
143. Tanihara, Y., Masuda, S., Sato, T., Katsura, T., Ogawa, O., and Inui, K. (2007). Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem. Pharmacol. 74, 359-371. doi: 10.1016/j.bcp.2007.04.010
144. Thangaraju, M., Ananth, S., Martin, P. M., Roon, P., Smith, S. B., Sterneck, E.,et al. (2006). c/ebp delta null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney. J. Biol. Chem. 281, 26769-26773. doi: 10.1074/jbc.C600189200
145. Tong, L., Phan, T. K., Robinson, K. L., Babusis, D., Strab, R., Bhoopathy, S.,et al. (2007). Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51, 3498-3504. doi: 10.1128/AAC.00671-07
146. Trajkovic-Arsic, M., Visser, T. J., Darras, V. M., Friesema, E. C., Schlott, B., Mittag, J.,et al. (2010). Consequences of monocarboxylate transporter 8 deficiency for renal transport and metabolism of thyroid hormones in mice. Endocrinology 151, 802-809. doi: 10.1210/en.2009-1053
147. Tramonti, G., Xie, P., Wallner, E. I., Danesh, F. R., and Kanwar, Y. S. (2006). Expression and functional characteristics of tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes. Am. J. Physiol. Renal Physiol. 291, F972-F980. doi: 10.1152/ajprenal.00110.2006
148. Tsuda, M., Terada, T., Ueba, M., Sato, T., Masuda, S., Katsura, T.,et al. (2009). Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J. Pharmacol. Exp. Ther. 329, 185-191. doi: 10.1124/jpet.108.147918
149. Tzvetkov, M. V., Dos Santos Pereira, J. N., Meineke, I., Saadatmand, A. R., Stingl, J. C., and Brockmoller, J. (2013). Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem. Pharmacol. 86, 666-678. doi: 10.1016/j.bcp.2013.06.019
150. Urakami, Y., Kimura, N., Okuda, M., and Inui, K.-I. (2004). Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm. Res. 21, 976-981. doi: 10.1023/B:PHAM.0000029286.45788.ad
151. Uwai, Y., Ida, H., Tsuji, Y., Katsura, T., and Inui, K. (2007). Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res. 24, 811-815. doi: 10.1007/s11095-006-9196-x
152. Vallon, V., Platt, K. A., Cunard, R., Schroth, J., Whaley, J., Thomson, S. C.,et al. (2011). SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 22, 104-112. doi: 10.1681/ASN.2010030246
153. Van Acker, B., Koopman, M., Arisz, L., Koomen, G., and De Waart, D. (1992). Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 340, 1326-1329. doi: 10.1016/0140-6736(92)92502-7
154. van Gelder, J., Deferme, S., Naesens, L., De Clercq, E., Van Den Mooter, G., Kinget, R.,et al. (2002). Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab. Dispos. 30, 924-930. doi: 10.1124/dmd.30.8.924
155. Vitart, V., Rudan, I., Hayward, C., Gray, N. K., Floyd, J., Palmer, C. N.,et al. (2008). SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat. Genet. 40, 437-442. doi: 10.1038/ng.106
156. Wenning, L. A., Friedman, E. J., Kost, J. T., Breidinger, S. A., Stek, J. E., Lasseter, K. C.,et al. (2008). Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 52, 3253-3258. doi: 10.1128/AAC.00005-08
157. Woodward, O. M., Kottgen, A., Coresh, J., Boerwinkle, E., Guggino, W. B., and Kottgen, M. (2009). Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. U.S.A. 106, 10338-10342. doi: 10.1073/pnas.0901249106
158. Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T.,et al. (2011). Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 66, 2092-2098. doi: 10.1093/jac/dkr272
159. Xu, J., Song, P., Nakamura, S., Miller, M., Barone, S., Alper, S. L.,et al. (2009). Deletion of the chloride transporter slc26a7 causes distal renal tubular acidosis and impairs gastric acid secretion. J. Biol. Chem. 284, 29470-29479. doi: 10.1074/jbc.M109.044396
160. Yamaguchi, H., Sugie, M., Okada, M., Mikkaichi, T., Toyohara, T., Abe, T.,et al. (2010). Transport of estrone 3-sulfate mediated by organic anion transporter OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin in OATP4C1. Drug Metab. Pharmacokinet. 25, 314-317. doi: 10.2133/dmpk.25.314
161. Yasui-Furukori, N., Uno, T., Sugawara, K., and Tateishi, T. (2005). Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin. Pharmacol. Ther. 77, 17-23. doi: 10.1016/j.clpt.2004.08.026
162. Young, J., Schafer, J., Fux, C. A., Furrer, H., Bernasconi, E., Vernazza, P.,et al. (2012). Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 26, 567-575. doi: 10.1097/QAD.0b013e32834f337c
163. Zhou, S. F., Wang, L. L., Di, Y. M., Xue, C. C., Duan, W., Li, C. G.,et al. (2008). Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 15, 1981-2039. doi: 10.2174/092986708785132870
164. Zhu, H. J., Appel, D. I., Grundemann, D., and Markowitz, J. S. (2010). Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J. Neurochem. 114, 142-149. doi: 10.1111/j.1471-4159.2010.06738.x